Europe
Owlstone Medical today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Produced from renewable materials, Minasolve’s new fragrance agent and skin moisturizer are innovative alternatives for preserving the quality of cosmetic products
Rewind Therapeutics today announces the establishment of a Scientific Advisory Board (SAB) composed of eminent scientists in the fields of multiple sclerosis, myelination and neuroscience drug discovery and development.
Antiepileptic drug use is associated with an increased risk of stroke among persons with Alzheimer’s disease, according to a new study from the University of Eastern Finland.
Gotham is developing a novel drug class targeting RNA-modifying proteins
ObsEva SA today announced that IMPLANT 2 Phase 3 clinical data of its novel, oral, oxytocin receptor antagonist, nolasiban, in patients undergoing IVF were presented at the 74th annual meeting ofthe American Society of Reproductive Medicine (ASRM), taking place in Denver, Colorado, October 6-10, 2018.
Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.
Sinntaxis announces today that it has entered into an option agreement with Acturum for an exclusive license to drug candidate AZD2066 for the development of a potentially pioneering treatment helping stroke survivors recover brain function.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Ionis Pharmaceuticals is on a roll. Days after securing regulatory approval from the FDA for Tegsedi, the company inked a deal worth more than $700 million with pharma giant Roche to develop IONIS-FB-L for the treatment of complement-mediated diseases.
PRESS RELEASES